World / Science & Health Nov 19, 2020
Pfizer-BioNTech coronavirus vaccine deliveries could start 'before Christmas'
Final trial results showed the vaccine had a 95% success rate and no serious side effects, the drugmakers said.
Pfizer-BioNTech coronavirus vaccine deliveries could start 'before Christmas'
Final trial results showed the vaccine had a 95% success rate and no serious side effects, the drugmakers said.
Pfizer reaches safety milestone for COVID-19 vaccine, CEO says
Pfizer Inc. Chief Executive Officer Albert Bourla said that a key safety milestone had been reached in the study of its COVID-19 vaccine, and the drugmaker is now preparing to seek an emergency-use authorization from U.S. regulators. Speaking at a virtual conference hosted by The ...
How Pfizer and BioNTech sprinted ahead in extraordinary race for a COVID-19 vaccine
Researchers were asked to tackle something that had never been done before: design a vaccine to stop a pandemic in its tracks in less than a year.
Moderna’s COVID-19 vaccine: What you need to know
Coming a week after similar news from Pfizer and BioNTech, Moderna's announcement offered more hope that there’s going to be a way out of the pandemic.
How the Moderna and Pfizer coronavirus vaccines stack up
The encouraging late-stage trial results from Pfizer Inc. and Moderna Inc. set a high bar for rivals that are expected to follow soon with their own pivotal reports.
Here’s to the immigrant heroes behind the BioNTech vaccine
Their journey as Turkish Germans cannot have been easy. Discrimination, overt or subtle, is rife in German society.
What happens to the other COVID-19 vaccines now?
If the vaccine created by Pfizer and partner BioNTech fails to live up to its promise, will any slower but better competitors have a chance?
Moderna COVID-19 vaccine trial reaches key goal to gauge merit
The bet among top experts in the field is that Moderna’s therapy will likely prove to be highly effective.
Why Pfizer’s vaccine won't be at the local pharmacy anytime soon
The vaccine's complex and supercold storage requirements are an obstacle for even the most sophisticated hospitals and may impact when and where it is available.
Pfizer's COVID-19 vaccine trial success signals breakthrough in pandemic battle
The vaccine candidate is more than 90% effective based on initial trial results, the drugmaker said Monday.
COVID-19 vaccine leaders make trial plans public in transparency push
The moves come amid increasing concern that the effort to develop a COVID-19 vaccine is becoming politicized.
Pfizer COVID-19 vaccine trial reports no major safety issues
Safety has been a paramount concern since AstraZeneca paused tests of the vaccine it's co-developing with the University of Oxford following an adverse event in a U.K.